Primary Endpoint Sample Clauses
Primary Endpoint. The primary endpoint will be the responder rate for lip fullness on the LFS2, which is defined as the proportion of subjects who show ≥ 1-point improvement on the LFS2 compared to baseline assessment, at Day 30 after last treatment received.
Primary Endpoint. Identifying factors and processes that may predict both interim and long-term patient resilience, their physical wellbeing and psychological outcomes of cancer and cancer treatment.
Primary Endpoint. IRRC-assessed ▇▇▇ and PFS, and OS, in intermediate-/poor-risk subjects with previously untreated advanced or metastatic RCC
Primary Endpoint. The primary endpoint is the occurrence of a Major Cardiac Event (▇▇▇▇) at one year. This is a composite end-point of death, myocardial infarction, and repeat target vessel revascularisation. See table 3. 4 for detailed definitions of endpoints.
Primary Endpoint. The primary endpoint is based on the mean reduction in total length of operative time. Operative time will be determined by the official recorded operative notes.
Primary Endpoint. Change in DENV viral load (DENV RNA as measured by RT-qPCR) from baseline
Primary Endpoint. Mean change in PED height at weeks 24 and 52.Proportion of patients with resolution of PED at weeks 24 and 52.
Primary Endpoint. Effectiveness of LiquiBand FIX8® will be assessed and compared to treatment with AbsorbaTack™ in subjects requiring laparoscopic (TEP and ▇▇▇▇) hernia repair. Success will be determined by improvement in pain not inferior to control device as measured by a VAS value (0 = no pain to 10 = most pain imaginable) from baseline (worst pain experienced within 1 month of screening visit) to six months post hernia repair. The statistical hypothesis is: H0: δT - δC ≥ 0.9[21, 22] H1: δT - δC < 0.9 [21, 22], where δ is the change from baseline (worst pain experienced within 1 month of screening visit) to 6-month on VAS for the appropriate treatment group. Secondary Endpoints: To assess efficacy and safety outcomes following ▇▇▇▇ or TEP laparoscopic groin hernia (femoral and inguinal) repair by LiquiBand FIX8® compared to AbsorbaTack™ by evaluating the following: • Recurrence rate in subjects following laparoscopic (TEP and ▇▇▇▇) groin hernia repair by LiquiBand FIX8® or control (AbsorbaTack™) at 2 weeks, 3 months, 6 months, and 12 months. The statistical hypothesis for the recurrence rate at 6 months is: H0: qT – qC ≥ 10%[25] H1: qT – qC < 10%[25], where q is the recurrence rate at 6 months for the appropriate treatment group. • Rate of successful hernia mesh fixation in subjects undergoing TEP and ▇▇▇▇ laparoscopic groin hernia repair. The statistical hypothesis is: H0: pC - pT ≥ 10% H1: pC - pT < 10%, where p is the rate of successful hernia mesh fixation at time of surgery for the appropriate treatment group. • Rate of successful peritoneal closure in subjects undergoing laparoscopic ▇▇▇▇ hernia repair. The statistical hypothesis is: H0: πC - πT ≥ 15% H1: πC - πT < 15%, where π is the rate of peritoneal closure at time of surgery for the appropriate treatment group. • Quality of Life assessed by the Carolinas Comfort Scale (CCS) Questionnaire prior to surgery and at 7 days, 14 days, 1 month, 3 months, 6 months, 9 months and 12 months following laparoscopic (TEP and ▇▇▇▇) groin hernia repair.
Primary Endpoint. The primary endpoint will be the proportion of subjects who achieve wound closure by or at 12-weeks post treatment with MIRODERM.
Primary Endpoint. The primary endpoint of this study is HDSS score reduction from a 3 or 4 at baseline to a 1 or 2 at 30 days post-treatment #2.